NascaCell announces a collaboration agreement with Aventis
"We are delighted to have the opportunity of this collaboration with Aventis. It further establishes the use of aptamers for accelerated target validation" said Dr. Andreas Jenne, CEO of NascaCell.
Aptamers are synthetic oligonucleotides that are able to bind to target proteins with high affinity and specificity. Because of the small molecule-like binding characteristics of aptamers, they typically show strong inhibition of protein function. NascaCell offers aptamers as tools for accelerated target validation and drug discovery.
Dr. Lucio A.A. van Rooijen at van Rooijen & Partners mediated the business deal.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.